Effect of hypothermia treatment on gentamicin pharmacokinetics in neonates with hypoxic-ischaemic encephalopathy: A systematic review and meta-analysis

Journal of Clinical Pharmacy and Therapeutics
D W ChoiS H An

Abstract

Hypothermia is the current standard therapy for asphyxiated neonates with hypoxic-ischaemic encephalopathy (HIE). Gentamicin is used for the empirical treatment of early-onset neonatal sepsis. We investigated the influence of hypothermia treatment on gentamicin pharmacokinetics and suggested the appropriate dosing recommendations for gentamicin in neonates with HIE receiving hypothermia treatment. We searched studies published until February 2017 in MEDLINE using PubMed, EMBASE and the Cochrane Library. Three independent reviewers screened the literature and extracted data from each study. All of the studies that reported the blood concentrations or pharmacokinetic parameters of gentamicin in hypothermic neonates with HIE were included in this review. Articles were excluded if they were not original research. A total of 8 observational studies met the inclusion criteria. Meta-analyses were performed in which the mean difference of gentamicin for the trough concentration and clearance between hypothermic and normothermic neonates were 0.81 mg/L (95% confidence interval [-0.07, 1.69]) and -0.21 mL/kg/min (95% confidence interval [-0.31, -0.12]), respectively. The factors affecting gentamicin clearance in hypothermic neonates with...Continue Reading

References

Jun 1, 1989·Antimicrobial Agents and Chemotherapy·R E Brummett, K E Fox
Oct 1, 1984·The American Journal of Medicine·R D MooreP S Lietman
Jan 1, 1984·The Journal of Infectious Diseases·R D MooreP S Lietman
May 15, 1980·The New England Journal of Medicine·C R SmithP S Lietman
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Jun 24, 2003·Statistics in Medicine·Norma TerrinIngram Olkin
Feb 24, 2004·Archives of Disease in Childhood. Fetal and Neonatal Edition·P ShahM Perlman
May 20, 2004·The Journal of Antimicrobial Chemotherapy·José M LanaoAlfonso Domínguez-Gil
Oct 14, 2005·The New England Journal of Medicine·Seetha ShankaranUNKNOWN National Institute of Child Health and Human Development Neonatal Research Network
Jun 20, 2006·The Journal of Antimicrobial Chemotherapy·Benito GarcíaIrene T Molina
Oct 3, 2009·The New England Journal of Medicine·Denis V AzzopardiUNKNOWN TOBY Study Group
Nov 26, 2009·Obstetrics and Gynecology·Mina Abbassi-GhanavatiF Gary Cunningham
Feb 23, 2010·International Journal of Surgery·David MoherUNKNOWN PRISMA Group
Apr 14, 2010·Clinical Pharmacokinetics·Marcel P H van den BroekCarin M A Rademaker
Jun 18, 2010·Early Human Development·Jennifer J KurinczukNadia Badawi
Dec 25, 2010·Journal of Perinatology : Official Journal of the California Perinatal Association·S ZanelliK Fairchild
Apr 6, 2011·Archives of Pediatrics & Adolescent Medicine·Susan E JacobsUNKNOWN Infant Cooling Evaluation Collaboration
Mar 19, 2013·Therapeutic Drug Monitoring·Liana F MarkCarlton K K Lee
May 25, 2013·Journal of Perinatology : Official Journal of the California Perinatal Association·A FrymoyerD Verotta
Jul 28, 2013·The Journal of Pediatrics·Elisa SmitMarianne Thoresen
Jun 19, 2014·British Journal of Clinical Pharmacology·Aline FuchsChantal Csajka
Jan 15, 2016·British Journal of Clinical Pharmacology·Yuma A BijleveldUNKNOWN PharmaCool study group
May 27, 2016·Journal of Clinical Pharmacology·Adam FrymoyerKrisa P Van Meurs

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.